Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Actinium Pharmaceuticals, Inc. (ATNM : AMEX)

• Company Description    Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for their ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. With their ARC approach, they seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Their lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SI Number of Employees: 25

• Price / Volume Information    Yesterday's Closing Price: $1.52 Daily Weekly Monthly 20 Day Moving Average: 231,770 shares Shares Outstanding: 31.44 (millions) Market Capitalization: $47.79 (millions) Beta: 0.26 52 Week High: $1.74 52 Week Low: $0.74 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 27.73% 29.08% 12 Week 81.60% 77.17% Year To Date 11.76% 5.09%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 100 Park Ave. 23rd Floor - NEW YORK,NY 10017 USA ph: 646-677-3870 fax: - investorrelations@actiniumpharma.com http://www.actiniumpharma.com

• General Corporate Information    Officers Sandesh Seth - Chairman and Chief Executive Officer June Almenoff - Director Jeffrey Chell - Director David Nicholson - Director Richard I. Steinhart - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 00507W206 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/13/26 Share - Related Items Shares Outstanding: 31.44 Most Recent Split Date: 8.00 (0.03:1) Beta: 0.26 Market Capitalization: $47.79 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.28 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.19 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/26

• Fundamental Ratios P/E Current FY Estimate: 8.22 Trailing 12 Months: 4.22 PEG Ratio: - Price Ratios Price/Book: 1.57 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 504.55% vs. Previous Quarter: 594.44% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/26 - - 06/30/26 - 83.42 03/31/26 - -218.66 ROA 09/30/26 - - 06/30/26 - 23.37 03/31/26 - -43.39 Current Ratio 09/30/26 - - 06/30/26 - 4.08 03/31/26 - 5.89 Quick Ratio 09/30/26 - - 06/30/26 - 4.08 03/31/26 - 5.89 Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - 32.23 03/31/26 - -26,078.89 Book Value 09/30/26 - - 06/30/26 - 0.97 03/31/26 - 0.07 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00

Powered by Zacks Investment Research ©